Revvity (NYSE:RVTY) Rating Increased to Hold at Zacks Research

Revvity (NYSE:RVTY) was upgraded by equities research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

Several other research firms have also issued reports on RVTY. Barclays boosted their price target on Revvity from $95.00 to $105.00 and gave the company an “equal weight” rating in a report on Thursday, May 7th. JPMorgan Chase & Co. lowered their price objective on Revvity from $96.00 to $90.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 6th. TD Cowen reiterated a “buy” rating on shares of Revvity in a research note on Wednesday, July 15th. Sanford C. Bernstein began coverage on shares of Revvity in a report on Friday, June 26th. They issued a “market perform” rating and a $115.00 target price for the company. Finally, Robert W. Baird set a $117.00 target price on shares of Revvity in a research note on Wednesday, May 6th. Three research analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $108.36.

Revvity Stock Up 3.4%

Shares of RVTY stock opened at $115.19 on Tuesday. The company has a current ratio of 1.80, a quick ratio of 1.41 and a debt-to-equity ratio of 0.36. Revvity has a 12 month low of $81.22 and a 12 month high of $118.30. The stock has a market cap of $12.85 billion, a P/E ratio of 54.85, a P/E/G ratio of 2.15 and a beta of 1.07. The company has a 50 day simple moving average of $107.53 and a two-hundred day simple moving average of $99.91.

Revvity (NYSE:RVTY) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $1.41 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.21 by $0.20. The firm had revenue of $711.00 million during the quarter, compared to the consensus estimate of $702.96 million. Revvity had a net margin of 8.16% and a return on equity of 8.34%. The company’s revenue for the quarter was down 1.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.18 EPS. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. On average, research analysts expect that Revvity will post 5.35 earnings per share for the current year.

Institutional Trading of Revvity

Several institutional investors have recently made changes to their positions in the business. Ascentis Independent Advisors purchased a new position in Revvity in the 1st quarter worth approximately $29,000. CYBER HORNET ETFs LLC purchased a new stake in Revvity during the 2nd quarter valued at approximately $32,000. MUFG Securities EMEA plc purchased a new stake in Revvity during the 2nd quarter valued at approximately $34,000. SJS Investment Consulting Inc. raised its position in shares of Revvity by 5,210.0% during the first quarter. SJS Investment Consulting Inc. now owns 531 shares of the company’s stock valued at $47,000 after buying an additional 521 shares during the last quarter. Finally, Headlands Technologies LLC bought a new stake in shares of Revvity during the second quarter valued at approximately $49,000. Hedge funds and other institutional investors own 86.65% of the company’s stock.

More Revvity News

Here are the key news stories impacting Revvity this week:

• Positive Sentiment: Q2 results exceeded expectations: Revvity reported adjusted earnings of $1.41 per share, above the $1.21–$1.23 consensus range, while revenue of $711 million topped estimates of approximately $703 million. EPS also increased from $1.18 in the prior-year quarter. Revvity raises annual profit, revenue forecasts on strong diagnostics demand
• Positive Sentiment: Full-year guidance was raised: The company now expects 2026 adjusted EPS of $5.30–$5.40, ahead of the $5.25 analyst consensus, and revenue of $2.8–$2.9 billion. Management cited strong diagnostics demand, wider margins and solid cash flow. RVTY Q2 Earnings Beat Estimates on Diagnostics Strength, 2026 View Up
• Positive Sentiment: Growth drivers are improving: Reports highlighted sustained demand for diagnostic testing and renewed interest in drug-development tools. AI-related applications and diagnostics growth are viewed as supporting Revvity’s longer-term outlook. RVTY Q2 deep dive: AI-driven demand and diagnostics growth shape outlook
• Neutral Sentiment: RVTY is trading near its 52-week high and above both its 50-day and 200-day moving averages, indicating strong momentum, although its elevated valuation leaves less room for execution disappointments.
• Negative Sentiment: Quarterly revenue still declined 1.3% year over year, showing that the broader recovery remains uneven despite the earnings beat and upgraded outlook.

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.